These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30879829)

  • 21. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine.
    Belmonti S; Lombardi F; Morandi M; Fabbiani M; Tordini G; Cauda R; De Luca A; Di Giambenedetto S; Montagnani F
    J Immunoassay Immunochem; 2016; 37(2):189-200. PubMed ID: 26506438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C.
    Sikkema DJ; Ziembiec NA; Jones TR; Hildreth SW; Madore DV; Quataert SA
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):218-23. PubMed ID: 15643011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
    Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
    Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children.
    Ryman J; Weaver J; Yee KL; Sachs JR
    Expert Rev Vaccines; 2022 Oct; 21(10):1515-1521. PubMed ID: 35997125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
    Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
    Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the pneumococcal conjugate vaccine on serotype distribution of adult non-invasive Streptococcus pneumoniae isolates in Tokai region, Japan, 2008-2016.
    Furuya Y; Yamagishi Y; Okade H; Kadota T; Funatsu T; Eto M; Nomura N; Mitsuyama J; Mikamo H
    J Infect Chemother; 2017 Jun; 23(6):394-399. PubMed ID: 28427991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum.
    Marchese RD; Puchalski D; Miller P; Antonello J; Hammond O; Green T; Rubinstein LJ; Caulfield MJ; Sikkema D
    Clin Vaccine Immunol; 2009 Mar; 16(3):387-96. PubMed ID: 19158284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
    Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
    BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 13-valent pneumococcal conjugate vaccine (PCV13).
    Jefferies JM; Macdonald E; Faust SN; Clarke SC
    Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.
    Ojal J; Hammitt LL; Gaitho J; Scott JAG; Goldblatt D
    Vaccine; 2017 Aug; 35(35 Pt B):4652-4657. PubMed ID: 28739116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assignment of Serotype-Specific IgG1, IgG2, and IgA Weight-Based Antibody Units to the Human Pneumococcal Standard Reference Serum, 007sp.
    Jones S; Finnegan K; Wee JH; D'Argoeuves P; Roalfe L; Byrne S; Heffernan S; Hunt A; Johnson M; Jones T; Pearce E; Richardson H; Thalasselis V; Goldblatt D
    mSphere; 2019 Jun; 4(3):. PubMed ID: 31217308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.